Advent France Biotechnology launches first Life Sciences seed-fund

Published: 20-Apr-2017
Finance Pharmaceutical

The venture capital fund will work as a technology transfer fund with multiple research institutions

French Life Sciences venture capital firm, Advent France Biotechnology, has begun he first closing of Advent France Biotechnology Seed-Fund I.

It is a venture capital fund that will work as a technology transfer fund with multiple research institutions and their respective technology transfer offices.

The Fund will back entrepreneurs and early-stage companies with the potential to deliver first or best-in-class breakthrough innovations for unmet medical needs.

Advent France Biotechnology Seed-Fund I will predominantly invest in France.

It is supported by Advent Life Sciences, one of Europe's venture teams investing in Life Sciences businesses and offering a direct access to a team of 15 investment professionals.

In addition to its relationship with Advent Life Sciences, Advent France Biotechnology intends to work closely with and to be complementary to existing French venture capital firms.

The Fund supported by the National Seed-Fund (Fonds National d’Amorcage), managed by Bpifrance under the Investments for the Future Program (PIA); the EU InnovFin Finance for Innovators initiative; and the European Fund for Strategic Investments, dedicated to seeding and building innovative Life Sciences companies in France.

See more

You may also like

Sustainability

Building strong foundations for a resilient and planet-friendly future

Read more
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  3. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  4. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Distribution

Tower Cold Chain launches live tracking and monitoring for pharmaceutical distribution

The upgrade allows customers to access real-time insights into shipments, facilitating the optimisation of cold chain processes
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection
Subscribe now